Preoperative Magnetic Resonance Guided Single-Dose Partial Breast Irradiation: 5-Year Results of the Prospective Single-Arm ABLATIVE Trial

离格 医学 磁共振成像 辐照 核医学 前瞻性队列研究 放射科 放射治疗 外科 物理 核物理学
作者
Yasmin A. Civil,Jeanine E. Vasmel,Ramona K. Charaghvandi,A.C. Houweling,Celien P.H. Vreuls,Paul J. van Diest,Arjen J. Witkamp,Annemiek Doeksen,Thijs van Dalen,Joeke Felderhof,Iris van Dam,Ben J. Slotman,Anna M. Kirby,Helena M. Verkooijen,Susanne van der Velde,Femke van der Leij,H.J.G.D. van den Bongard
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:121 (3): 613-622 被引量:3
标识
DOI:10.1016/j.ijrobp.2024.07.2326
摘要

Preoperative partial breast irradiation (PBI) can increase accuracy of target volume definition and decrease irradiated volumes compared with postoperative PBI. In the ABLATIVE trial (NCT02316561), 15 of 36 patients achieved pathologic complete response 6 to 8 months after preoperative PBI and breast-conserving surgery (BCS). We now present the 5-year results. The ABLATIVE trial is a Dutch prospective cohort study conducted in 4 hospitals. Women aged ≥50 years with unifocal, nonlobular breast cancer, estrogen receptor-positive, HER2-negative, and a tumor negative sentinel node were treated between 2015 and 2018 with preoperative single-dose PBI followed by BCS after 6 or 8 months. The primary endpoint was pathologic complete response. Secondary endpoints were annually evaluated oncological outcomes, toxicity, cosmetic outcome (assessed by patients and physicians), and quality of life. Thirty-six patients were treated with BCS 6 (n = 15) and 8 (n = 21) months following PBI. Median tumor size was 13 mm (IQR 9-16 mm). After a median follow-up of 5.5 years (IQR, 5.1-6.0), 2 (6%) patients had ipsilateral breast events and 2 (6%) distant metastases. The 5-year overall survival was 94% (95% CI, 87-100). The 5-year cumulative incidence of clinician-reported grade 1/2 breast fibrosis and breast discomfort/pain were 94%/6% and 75%/6%, respectively. The proportion of patients (very) satisfied with the cosmetic results was 89% at baseline and 78% at 5 years. Cosmetic results evaluated using the BCCT.core software were excellent or good in all patients. The 4-year median global quality of life score was 83 (IQR, 67-92), similar to baseline (83; IQR, 75-83; P = .42). Preoperative single-dose PBI and BCS may be an oncologically safe treatment with mild late toxicity and no decline in cosmetic results and quality of life during 5 years of follow-up. This means that preoperative instead of standard postoperative irradiation has the potential to challenge the current clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
桐桐应助Dora采纳,获得10
2秒前
香蕉觅云应助糟糕的铁锤采纳,获得10
2秒前
4秒前
7秒前
7秒前
10秒前
沉静白卉完成签到,获得积分10
11秒前
guo发布了新的文献求助200
11秒前
隐形曼青应助渡川采纳,获得10
11秒前
大海完成签到,获得积分10
11秒前
13秒前
yuyuyu完成签到,获得积分10
14秒前
赘婿应助morena采纳,获得30
14秒前
masheng发布了新的文献求助10
14秒前
落后凝莲完成签到,获得积分20
15秒前
16秒前
隐形曼青应助动听的世立采纳,获得10
17秒前
17秒前
17秒前
西瓜妈妈完成签到,获得积分20
19秒前
时雨完成签到,获得积分10
19秒前
21秒前
21秒前
Ava应助hanchangcun采纳,获得10
22秒前
ElbingX发布了新的文献求助20
22秒前
lemongulf完成签到 ,获得积分10
23秒前
23秒前
机灵的成协完成签到,获得积分10
24秒前
Coral.发布了新的文献求助10
24秒前
ShengjieZi发布了新的文献求助10
25秒前
25秒前
26秒前
26秒前
科研通AI5应助Ultraman45采纳,获得10
27秒前
可爱的函函应助fjiang2003采纳,获得10
28秒前
gky完成签到,获得积分10
28秒前
隐形曼青应助机灵的成协采纳,获得10
29秒前
香蕉觅云应助天荷采纳,获得10
29秒前
赘婿应助天荷采纳,获得10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976235
求助须知:如何正确求助?哪些是违规求助? 3520399
关于积分的说明 11203166
捐赠科研通 3256989
什么是DOI,文献DOI怎么找? 1798580
邀请新用户注册赠送积分活动 877738
科研通“疑难数据库(出版商)”最低求助积分说明 806516